F092 The Morbilliform Eruption: Differentiation and Treatment of Viral, Low-Risk Drug, Severe Cutaneous Adverse Reactions, and GVHD
DESCRIPTION
The morbilliform eruption is the most common cutaneous morphology encountered in the hospital setting. Despite its frequency, there is a dearth of literature and lectureships available to support evidenced-based guidelines especially for evaluation of the undifferentiated patient. This session will focus on the early and accurate diagnosis and differentiation of low-risk drug eruptions, severe cutaneous adverse reactions, viral eruptions, and GVHD in the adult patient.
LEARNING OBJECTIVES
Identify distinguishing characteristics that allow differentiation of morbilliform eruptions into high-risk and low-risk categories
Differentiate early severe cutaneous adverse reactions by morphologic differences, followed by confirmatory testing
Recognize laboratory testing and algorithms available to support the diagnosis of drug eruptions, viral reactions, and Graft-Versus-Host Disease.
SCHEDULE
1:00 PM
Introduction and Differentiation of Low-Risk from High Risk Exanthems
Benjamin Kaffenberger, MD, MS, FAAD
1:10 PM
Differentiation of High-Risk Exanthems: The Severe Cutaneous Adverse Reactions
Rachel Kirven, MD, FAAD
1:35 PM
Chemotherapy and Immunotherapy Associated Morbilliform Eruptions
Brittany L Dulmage, MD, FAAD
1:55 PM
Morbilliform eruptions in the stem cell transplant setting
Connie Shi, MD, FAAD
2:10 PM
Viral Exanthems and Viral Reactivation in DRESS Syndrome
Anna Cogen, MD, PhD, FAAD
2:30 PM
Immune pathogenesis separating low risk exanthems from severe cutaneous adverse reactions
Eric Mukherjee, MD, PhD
2:50 PM
Questions
DIRECTOR
Benjamin Kaffenberger, MD, MS, FAAD
SPEAKERS
Anna Cogen, MD, PhD, FAAD
Brittany L Dulmage, MD, FAAD
Rachel Kirven, MD, FAAD
Eric Mukherjee, MD, PhD
Connie Shi, MD, FAAD
DISCLOSURES
Anna Cogen, MD, PhD, FAAD
No financial relationships exist with ineligible companies.
Brittany L Dulmage, MD, FAAD
Azitra, Inc – Investigator(Grants/Research Funding); Hoth Therapeutics – Data Safety Monitoring Board(Honoraria); Novocure – Consultant (1099 relationship)(Honoraria); Xencor – Consultant (1099 relationship)(Fees);
Benjamin Kaffenberger, MD, MS, FAAD
Almirall – Consultant (1099 relationship)(Honoraria); Boehringer Ingelheim – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Dermatology Foundation – Investigator(Grants/Research Funding); Eli Lilly and Company – Consultant (1099 relationship)(Honoraria); HCW Biologics – Investigator(Grants/Research Funding); InflaRx – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); Janssen Biotech – Investigator(Grants/Research Funding); Leo Pharma – Investigator(Grants/Research Funding); National Comprehensive Cancer Network – Speaker(Honoraria);
Rachel Kirven, MD, FAAD
No financial relationships exist with ineligible companies.
Eric Mukherjee, MD, PhD
No financial relationships exist with ineligible companies.
Connie Shi, MD, FAAD
No financial relationships exist with ineligible companies.